FIELD: medicine.
SUBSTANCE: group of invention presents methods for prevention and treatment of osteolysis, cancer metastases and bone loss caused by cancer metastases by the introduction of M-CSF antagonist combined with bisphosphonate in an individual.
EFFECT: said group of inventions enables achieving effective treatment of the osteolytic disorder.
21 cl, 32 dwg, 3 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CD131-BINDING PROTEINS AND THEIR APPLICATIONS | 2016 |
|
RU2773927C2 |
| IMMUNOCYTOKINES BASED ON IL-15 AND IL-15Rα OF THE SUSHI DOMAIN | 2012 |
|
RU2763298C2 |
| ANTIBODY TO TIGIT AND ITS USE | 2019 |
|
RU2786434C2 |
| CD123-SPECIFIC CHIMERIC ANTIGENIC RECEPTORS FOR CANCER IMMUNOTHERAPY | 2015 |
|
RU2727290C2 |
| ADAM9-BINDING MOLECULES AND THEIR APPLICATION METHODS | 2017 |
|
RU2783619C2 |
| HUMANIZED ANTI-PSMA ANTIBODIES | 2019 |
|
RU2794450C2 |
| AGENTS FOR THE TREATMENT OF CLAUDINE-EXPRESSING CANCER DISEASES | 2013 |
|
RU2798990C2 |
| ANTI-PVRIG ANTIBODIES AND METHODS OF USING | 2016 |
|
RU2732042C2 |
| MONOCLONAL BINDING AGENTS, THEIR DRUG CONJUGATES AND THEIR APPLICATIONS | 2017 |
|
RU2744914C2 |
| MONOCLONAL ANTIBODY THAT SPECIFICALLY BINDS TO CSF-1R | 2020 |
|
RU2751249C1 |
